Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) EBITDA Margin: 2014-2024

Historic EBITDA Margin for Collegium Pharmaceutical (COLL) over the last 11 years, with Dec 2024 value amounting to 26.91%.

  • Collegium Pharmaceutical's EBITDA Margin rose 779.00% to 29.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.74%, marking a year-over-year decrease of 1155.00%. This contributed to the annual value of 26.91% for FY2024, which is 255.00% down from last year.
  • Collegium Pharmaceutical's EBITDA Margin amounted to 26.91% in FY2024, which was down 8.67% from 29.46% recorded in FY2023.
  • In the past 5 years, Collegium Pharmaceutical's EBITDA Margin registered a high of 29.46% during FY2023, and its lowest value of 6.37% during FY2021.
  • In the last 3 years, Collegium Pharmaceutical's EBITDA Margin had a median value of 26.91% in 2024 and averaged 21.18%.
  • In the last 5 years, Collegium Pharmaceutical's EBITDA Margin skyrocketed by 2,614bps in 2020 and then crashed by 1,177bps in 2021.
  • Yearly analysis of 5 years shows Collegium Pharmaceutical's EBITDA Margin stood at 18.14% in 2020, then tumbled by 1,177bps to 6.37% in 2021, then soared by 81bps to 7.18% in 2022, then surged by 2,228bps to 29.46% in 2023, then crashed by 255bps to 26.91% in 2024.